Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study of Monoclonal Antibody 3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to 13-cis-Retinoic Acid Plus GM-CSF in High Risk Stage 4, Primary Refractory Neuroblastoma Patients

NCT00969722 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT00969722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00969722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study of Monoclonal Antibody 3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to 13-cis-Retinoic Acid Plus GM-CSF in High Risk Stage 4, Primary Refractory Neuroblastoma Patients
Lead sponsor
United Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2009
Completion date
Not reported
Enrollment
1 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

primary refractory neuroblastoma